Skip to content
Oxcia

Oxcia

  • About us
    • About us
    • Management
    • Board
    • Scientific Advisory Board
    • Collaborators
    • Partnerships
    • History
    • Careers
  • Scientific Platform
    • Scientific Platform
    • Glossary
  • Pipeline
    • Pipeline
    • OXC-101
    • OXC-201
  • Investors
    • Investors
    • Governance
    • Ownership structure
    • Financial reports
    • Presentations
    • Upcoming events
    • Investor contact
  • Investerare
    • Investerare
    • Bolagsstyrning
    • Bolagsstämmor
    • Ägarstruktur
    • Finansiella rapporter
    • Pressmeddelanden
    • Presentationer
    • Kalender
    • Investerarkontakt
  • News and Press
  • Contact
  • Search

Home › News and Press › Press releases › Page 3

News and Press releases

View all News Press releases

Oxcia has been awarded a grant of 3 million SEK for a study in refractory AML patients

April 3, 2023 · Press releases
Read article

Three abstracts on OXC-101 selected for poster presentations at AACR 2023

March 30, 2023 · Press releases
Read article

New pre-clinical study shows that OXC-201 may be a promising treatment for IPF (pulmonary fibrosis)

March 2, 2023 · Press releases
Read article

The EIC has awarded Oxcia AB with a EIC transition grant of 2.5 million Euros for development of OXC-201.

February 24, 2023 · Press releases
Read article

Oxcia AB publishes Year-End Report for 2022

February 15, 2023 · Press releases
Read article

Data show OXC-201 may be a promising treatment for allergic asthma.

October 21, 2022 · Press releases
Read article

Enrolment completed and recommended phase II dose reached for OXC-101

October 14, 2022 · Press releases
Read article

Oxcia AB is strengthening the organization further

September 6, 2022 · Press releases
Read article

New studies show OXC-101 further improves conventional chemotherapy treatment in Acute Myelom Leukemia (AML)

March 23, 2022 · Press releases
Read article

Oxcia reports positive interim data from clinical phase I study in advanced solid cancers

January 17, 2022 · Press releases
Read article

Oxcia contracts Patheon for manufacturing and further strengthens the organization

· Press releases
Read article
« Back 1 2 3 Forward »

Contact us

Oxcia AB
Norrbackagatan 70C
113 34 Stockholm, Sweden

+46 (0)73 270 96 05

info@oxcia.com

Privacy policy

Menu

  • About us
    • About us
    • Management
    • Board
    • Scientific Advisory Board
    • Collaborators
    • Partnerships
    • History
    • Careers
  • Scientific Platform
    • Scientific Platform
    • Glossary
  • Pipeline
    • Pipeline
    • OXC-101
    • OXC-201
  • Investors
    • Investors
    • Governance
    • Ownership structure
    • Financial reports
    • Presentations
    • Upcoming events
    • Investor contact
  • Investerare
    • Investerare
    • Bolagsstyrning
    • Bolagsstämmor
    • Ägarstruktur
    • Finansiella rapporter
    • Pressmeddelanden
    • Presentationer
    • Kalender
    • Investerarkontakt
  • News and Press
  • Contact
  • Search

Social media

  • Linkedin

OXC-201

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Innovation Council. Neither the European Union nor the European Innovation Council can be held responsible for them.


an EIC project aiming to bring hope to IPF patients

© Copyright Oxcia 2025 · Legal Notice · Information About Cookies

Search

More results

Generic filters